

# Geoffrey I Shapiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3990804/publications.pdf>

Version: 2024-02-01

140  
papers

15,176  
citations

25423

59  
h-index

21843

118  
g-index

144  
all docs

144  
docs citations

144  
times ranked

23377  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. <i>Clinical Cancer Research</i> , 2022, 28, 298-307.	3.2	12
2	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I open-label, dose escalation study. <i>International Journal of Cancer</i> , 2022, 150, 993-1006.	2.3	28
3	A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 163, 19-26.	0.9	19
4	CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. <i>Future Oncology</i> , 2022, , .	1.1	4
5	Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100456.	1.5	11
6	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	3.2	22
7	A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and CDK12-loss metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS213-TPS213.	0.8	2
8	Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).. <i>Journal of Clinical Oncology</i> , 2022, 40, 119-119.	0.8	2
9	Abstract P2-07-13: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlates of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P2-07-13-P2-07-13.	0.4	0
10	A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS195-TPS195.	0.8	1
11	Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer. <i>Cancer Research</i> , 2022, 82, OT2-01-02-OT2-01-02.	0.4	0
12	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K $\beta$ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	3.2	11
13	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 45.	2.3	16
14	Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2022, 126, 1027-1036.	2.9	18
15	Report of the First International Symposium on NUT Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2493-2505.	3.2	23
16	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	3.2	10
17	Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2580.	1.7	14
18	A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 163-174.	1.2	15

#	ARTICLE	IF	CITATIONS
19	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 983-991.	3.2	29
20	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2021, 124, 744-753.	2.9	65
21	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 66-82.	5.7	126
22	Pharmacokinetics and Safety of PTC596, a Novel Tubulin- $\beta$ -Binding Agent, in Subjects With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 940-949.	0.8	11
23	Clinical Efficacy of Olaparib in <i>IDH1/IDH2</i> -Mutant Mesenchymal Sarcomas. <i>JCO Precision Oncology</i> , 2021, 5, 466-472.	1.5	24
24	EZH2 inhibition activates a dsRNA- $\beta$ -STING- $\beta$ -interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 444-456.	5.7	118
25	Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2991-3000.	2.0	18
26	MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. <i>Cell Reports</i> , 2021, 34, 108808.	2.9	24
27	<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 2488-2505.	7.7	46
28	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine $\pm$ cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 510-519.	2.9	59
29	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 520-527.	2.9	37
30	Crizotinib in Patients With MET-Amplified NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1017-1029.	0.5	84
31	A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. <i>Nature Cancer</i> , 2021, 2, 598-610.	5.7	168
32	Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4710-4716.	3.2	51
33	Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6622-6637.	3.2	7
34	Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1604-1612.	1.2	17
35	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	3.2	74
36	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). <i>JCO Precision Oncology</i> , 2021, 5, 1432-1442.	1.5	29

#	ARTICLE	IF	CITATIONS
37	A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. <i>Nature Communications</i> , 2021, 12, 5574.	5.8	32
38	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1105-1124.	1.1	26
39	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	0.6	20
40	Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 786120.	1.3	5
41	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , 2021, 184, 6119-6137.e26.	13.5	201
42	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 3133-3140.	0.6	2
43	Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 419-432.	1.2	55
44	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz093.	1.4	126
45	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5588-5597.	3.2	7
46	CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. <i>Molecular Cell</i> , 2020, 80, 410-422.e6.	4.5	38
47	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	3.2	95
48	Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 115-126.	1.8	16
49	Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1406-1414.	1.9	51
50	Biomarker-Guided Development of DNA Repair Inhibitors. <i>Molecular Cell</i> , 2020, 78, 1070-1085.	4.5	157
51	Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 957-968.	5.1	140
52	First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE <sub>2</sub> -receptor E-type 4 (EP4), in patients with advanced cancers. , 2020, 8, e000222.		34
53	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. <i>Nature Communications</i> , 2020, 11, 1459.	5.8	176
54	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. <i>Future Oncology</i> , 2020, 16, 4289-4301.	1.1	12

#	ARTICLE	IF	CITATIONS
55	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz094.	1.4	114
56	The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. <i>Clinical Cancer Research</i> , 2019, 25, 6127-6140.	3.2	104
57	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. <i>Clinical Cancer Research</i> , 2019, 25, 5808-5817.	3.2	66
58	PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 722-737.	7.7	433
59	MicroRNA-Mediated Suppression of the TGF- $\beta$ Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. <i>Cell Reports</i> , 2019, 26, 2667-2680.e7.	2.9	101
60	Olaparib and $\beta$ -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	5.1	191
61	Functional profiling of nucleotide Excision repair in breast cancer. <i>DNA Repair</i> , 2019, 82, 102697.	1.3	10
62	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 814-821.	1.9	30
63	RAS- $\beta$ MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i> -Amplified Lung Cancer and Underlies a Rationale for Upfront <i>FGFR</i> - $\beta$ MEK Blockade. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1526-1539.	1.9	39
64	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	7.7	283
65	First-in-human trial of the PI3K- $\beta$ -selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324.	2.0	29
66	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	7.7	503
67	Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in <i>KRAS</i> -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 31572-31589.	0.8	42
68	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. <i>Cancer Discovery</i> , 2018, 8, 1404-1421.	7.7	311
69	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	7.7	256
70	A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6085-6085.	0.8	11
71	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	2.9	59
72	Evaluation of BGI398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	0.8	345

#	ARTICLE	IF	CITATIONS
73	First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 315-323.	1.2	33
74	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	2.0	170
75	A Phase Iâ€”II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4095-4106.	3.2	213
76	Sensitizing HR-proficient cancers to PARP inhibitors. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1299272.	0.3	4
77	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3520-3528.	3.2	19
78	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 296-304.	1.3	64
79	Synergy of WEE1 and mTOR Inhibition in Mutant <i>KRAS</i>-Driven Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 6993-7005.	3.2	29
80	Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. <i>British Journal of Cancer</i> , 2017, 117, 1258-1268.	2.9	42
81	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. <i>Clinical Cancer Research</i> , 2017, 23, 6661-6672.	3.2	110
82	Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search. <i>Cancer Cell</i> , 2017, 32, 721-723.	7.7	11
83	Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11048-11048.	0.8	2
84	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016, 1, e87062.	2.3	340
85	Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Nonâ€”Small Cell Lung Cancer, and Other Solid Tumors. <i>Cancer Discovery</i> , 2016, 6, 740-753.	7.7	565
86	Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4371-4380.	0.8	203
87	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 305-312.	1.1	37
88	Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. <i>Breast Care</i> , 2016, 11, 167-173.	0.8	92
89	A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 5696-5705.	3.2	245
90	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2016, 17, 2367-2381.	2.9	215



#	ARTICLE	IF	CITATIONS
91	ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 549-558.	1.1	15
92	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2939-2949.	3.2	51
93	Targeting CDK4 and CDK6: From Discovery to Therapy. <i>Cancer Discovery</i> , 2016, 6, 353-367.	7.7	717
94	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3227-3237.	3.2	85
95	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. <i>New England Journal of Medicine</i> , 2015, 373, 428-437.	13.9	438
96	Disruption of DNA Repair by Cell Cycle and Transcriptional CDK Inhibition. <i>Cancer Drug Discovery and Development</i> , 2015, , 413-430.	0.2	0
97	DNA-PKâ€”A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. <i>Clinical Cancer Research</i> , 2015, 21, 925-933.	3.2	74
98	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 1108-1114.	1.2	44
99	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. <i>Cancer Discovery</i> , 2015, 5, 1137-1154.	7.7	657
100	Intratumoral Heterogeneity in <i>EGFR</i>-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2015, 75, 4372-4383.	0.4	108
101	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1888-1895.	3.2	99
102	First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 87-97.	3.2	78
103	Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGF $\beta$ ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e90353.	1.1	328
104	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 233-245.	3.2	142
105	The Biology and Clinical Development of MEK Inhibitors for Cancer. <i>Drugs</i> , 2014, 74, 2111-2128.	4.9	35
106	Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	45
107	Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Nonâ€”Small Cell Lung Cancer and Predict Strategies to Overcome Resistance. <i>Clinical Cancer Research</i> , 2014, 20, 1204-1211.	3.2	57
108	A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 937-945.	1.2	57

#	ARTICLE	IF	CITATIONS
109	Aurora Kinase Inhibition As an Anticancer Strategy. <i>Journal of Clinical Oncology</i> , 2014, 32, 57-59.	0.8	50
110	Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors. , 2014, , .		5
111	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17041-17046.	3.3	225
112	Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 370-380.	1.2	59
113	Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2530-2530.	0.8	19
114	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4973-4985.	3.2	141
115	Chemotherapy-induced p53-dependent and -independent DNA damage responses are enhanced by poly(ADP-ribose) polymerase (PARP) inhibition in BRCA-proficient cancer cells. <i>Cell Cycle</i> , 2012, 11, 432-432.	1.3	0
116	Cyclin-dependent kinase 4/6 inhibition in cancer therapy. <i>Cell Cycle</i> , 2012, 11, 3913-3913.	1.3	19
117	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. <i>Blood</i> , 2012, 119, 4597-4607.	0.6	278
118	Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 891-898.	1.1	22
119	Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3163-3169.	3.2	470
120	The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 555-562.	1.1	31
121	Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 909-916.	0.8	498
122	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. <i>Nature Medicine</i> , 2011, 17, 875-882.	15.2	238
123	Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3431-3442.	3.2	29
124	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 849-860.	3.2	58
125	Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer. <i>Current Oncology Reports</i> , 2010, 12, 87-94.	1.8	54
126	Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1199-1212.	1.5	90



#	ARTICLE	IF	CITATIONS
127	Targeting Cyclin-Dependent Kinases for Cancer Therapy. , 2010, , 167-185.		0
128	Heat Shock Protein 90 Inhibition in Lung Cancer. Journal of Thoracic Oncology, 2008, 3, S152-S159.	0.5	70
129	Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. Journal of Clinical Oncology, 2006, 24, 1770-1783.	0.8	927
130	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Research, 2006, 66, 11389-11398.	0.4	112
131	AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9. Cancer Research, 2006, 66, 435-444.	0.4	74
132	Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer Cells. Cancer Research, 2006, 66, 9270-9280.	0.4	143
133	Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice. Oncogene, 2005, 24, 1683-1688.	2.6	24
134	A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2004, 10, 4680-4687.	3.2	65
135	Bioluminescent imaging of Cdk2 inhibition in vivo. Nature Medicine, 2004, 10, 643-648.	15.2	91
136	Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol. Clinical Cancer Research, 2004, 10, 4270s-4275s.	3.2	175
137	The Physiology of p16 <sup>INK4A</sup> -Mediated G1 Proliferative Arrest. Cell Biochemistry and Biophysics, 2000, 33, 189-197.	0.9	51
138	Anticancer drug targets: cell cycle and checkpoint control. Journal of Clinical Investigation, 1999, 104, 1645-1653.	3.9	367
139	Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3025-3028.	1.8	26
140	Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors. , 0, .		10